Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 9:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 10,850 matching trials from the live ClinicalTrials.gov search.
Terminated Phase 1Phase 2 Interventional Results available

A Factor IX Gene Therapy Study (FIX-GT)

NCT03369444
Conditions
Hemophilia B
Interventions
FLT180a
Biological
Lead sponsor
University College, London
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
Interventions
clofarabine, cyclophosphamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
2 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Pompe Disease
Interventions
Rituximab, Miglustat
Drug
Lead sponsor
University of Florida
Other
Eligibility
Up to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Leigh Syndrome
Interventions
EPI-743
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
1 Year to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
4
States / cities
Stanford University, California • Akron, Ohio • Houston, Texas + 1 more
Conditions
Sickle Cell Disease
Interventions
Blood draw, Nasopharyngeal wash
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Encephalopathy, Developmental Delay and Behavioral Changes, Cord Tumor Compression or Instability, Cord Tethering or Malformation
Interventions
Intermittent Propofol Sedation, Continuous Propofol Sedation
Procedure
Lead sponsor
Corewell Health West
Other
Eligibility
1 Month to 18 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Grand Rapids, Michigan
Conditions
Hypertension
Interventions
6R-BH4 (sapropterin dihydrochloride)
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 21 more
Conditions
Gout
Interventions
Denosumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Cystic Fibrosis
Interventions
Tobramycin for Inhalation
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 5 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
9
States / cities
Palo Alto, California • Denver, Colorado • Baltimore, Maryland + 6 more
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of LQT-1213 in Healthy Adults

NCT05759962
Conditions
Long QT Syndrome
Interventions
LQT-1213, Placebo
Drug · Other
Lead sponsor
Thryv Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cypress, California
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Assessment of Barley and Oat Phytochemicals

NCT01303562
Conditions
Healthy
Interventions
Whole grain oats and barley
Other
Lead sponsor
Tufts University
Other
Eligibility
40 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting No phase listed Observational

Diagnostic Odyssey: Whole Genome Sequencing (WGS)

NCT03458962
Conditions
Genetic Disease, Genetic Syndrome
Interventions
Genetic Enrollees
Genetic
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2070
U.S. locations
1
States / cities
Miami, Florida
Conditions
Vascular Ehlers-Danlos Syndrome
Interventions
Enzastaurin, Placebo
Drug
Lead sponsor
Aytu BioPharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Englewood, Colorado
Completed Phase 1 Interventional Accepts healthy volunteers

Mass Balance Study of [14C]LC350189 in Healthy Volunteers

NCT04070846
Conditions
Gout, Hyperuricemia
Interventions
[14C] LC350189
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Conditions
Atopic Dermatitis
Interventions
PF-04965842 200 mg, PF-04965842 100 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Largo, Florida + 5 more
Terminated Phase 3 Interventional Results available

Effects of PTH Replacement on Bone in Hypoparathyroidism

NCT00395538
Conditions
Hypoparathyroidism, DiGeorge Syndrome
Interventions
PTH 1-34
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Arthralgia, Bunion, Hallux Valgus, Pain
Interventions
Tapentadol (CG5503), oxycodone, placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Glendale, California • Pasadena, Maryland • Austin, Texas + 4 more
Completed Not applicable Interventional Results available

Duchenne Muscular Dystrophy Clinical Trial

NCT01874275
Conditions
Duchenne Muscular Dystrophy
Interventions
VECTTOR
Device
Lead sponsor
Alan Neuromedical Technologies, LLC
Industry
Eligibility
8 Years to 20 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Tourette Syndrome
Interventions
Modified Atkins diet
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Enrolling by invitation No phase listed Observational

SLC13A5 Deficiency Natural History Study - Remote Only

NCT04681781
Conditions
Citrate Transporter Deficiency, Epilepsy, Rare Diseases, Movement Disorders, Genetic Disorder, SLC13A5 Deficiency, EIEE25, Kohlschutter-Tonz Syndrome (non-ROGDI), 17p13.1 Deletions Confined to SLC13A5 Gene, Citrate Transporter Disorder
Interventions
Not listed
Lead sponsor
TESS Research Foundation
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Telangiectasia, Hereditary Hemorrhagic, Epistaxis
Interventions
Sterile saline, Bevacizumab, Estriol, Tranexamic Acid
Drug
Lead sponsor
James Gossage
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 3 more
Conditions
Von Hippel-Lindau Syndrome
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
0 Years to 11 Years · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
24
States / cities
Phoenix, Arizona • Long Beach, California • Orange, California + 20 more
Conditions
Cardiomyopathy, Dilated
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
Up to 22 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
7
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 4 more